Relmada Therapeutics (RLMD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Relmada Therapeutics (RLMD) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.02 of bullish evidence against -0.34 bearish.

Relmada Therapeutics last closed at $3.39, +6.94% on the session.

Against the IVW growth benchmark the position is +6.14% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

9 graded predictions for RLMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Relmada Therapeutics in the 18th percentile on return on equity, where 100 is best.

Relmada Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $338.14M.

StockMap tracks Relmada Therapeutics as the 84th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Relmada Therapeutics ranks 109th of 151 in the group, against a group median of -0.08.